Results 101 to 110 of about 315,867 (288)

Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Cell Death and Disease
Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents.
Sk. Kayum Alam, Anuradha Pandit, Li Wang, Seyedeh Sahar Mortazavi Farsani, Britteny A. Thiele, Parvathy Manoj, Marie Christine Aubry, Vivek Verma, Charles M. Rudin, Ying-Chun Lo, Luke H. Hoeppner   +10 more
doaj   +1 more source

Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model

Neurobiology of Disease, 2004
Brain cannabinoid CB1 receptors are expressed in neural areas that contribute to movement such as basal ganglia, where they co-localize with dopamine D1 and D2 receptors.
Fadwa El Banoua, Isabel Caraballo, Juan A Flores, Beatriz Galan-Rodriguez, Emilio Fernandez-Espejo   +4 more
doaj   +1 more source

Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice

Neurobiology of Disease, 2006
Genetic and biochemical abnormalities associated with α-synuclein are implicated in the etiology of Parkinson's disease (PD). In this study, altered locomotor behavior linked to the expression of mutant or wildtype human α-synuclein was investigated ...
Erica L. Unger, David J. Eve, Xiomara A. Perez, Dawn K. Reichenbach, Yanqun Xu, Michael K. Lee, Anne M. Andrews   +6 more
doaj   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy, Frederique Leh, Alexandra Foubert‐Samier, Soizic Leguy Bonnet, Guillaume Baille, Margherita Fabbri, Margaux Dunoyer, Lise Mantisi, Caroline Giordana, Anaïs El Ouartassi, Olivier Rascol, Wassilios G. Meissner, David Bendetowicz, Marie Vanel, David Grabli, Fabienne Ory‐Magne, Sophie Drapier   +16 more
wiley   +1 more source

Brexpiprazole mitigates hyperprolactinaemia induced by paliperidone in a patient with a history of skin reaction to aripiprazole: case report introducing a new therapeutic approach

BJPsych Open
Hyperprolactinaemia is a common adverse effect of antipsychotic medication, primarily resulting from dopamine D2 receptor blockade. It is characterised by menstrual irregularities, gynaecomastia, galactorrhoea and, with prolonged exposure, an increased ...
Marie Humbert-Claude, Tiphaine Barbé, Maria-Cristina Ionescu, Mehrnoush Khasian, Omar Timothy Khachouf, Anne-Laure Blanc, Delphine Lemoullec-Tourtier, Nicolas Widmer   +7 more
doaj   +1 more source

Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch, Athena Mancini, Adham Elsherbini, Jason Yuen, Andres Lozano   +4 more
wiley   +1 more source

Therapeutic challenges of giant invasive cystic macroprolactinoma

Endocrinology, Diabetes & Metabolism Case Reports
Giant cystic prolactinomas are extremely rare, with only four cases previously reported in the literature. Herein, we report the case of a 59-year-old male who presented with an acute decline in visual acuity.
S Mekni, H Khiari, S Bouali, R Laamouri, S Essayeh, I Rojbi, I Ben Nacef   +6 more
doaj   +1 more source

Dopamine /

, 2005
Dopamine is a major neurotransmitter of the brain involved in the control of movement, emotion, and cognition; disturbance in dopamine function is associated with disorders like Parkinsons disease, schizophrenia and attention deficit hyperactivity ...
Dunnett, S. B.(Stephen B.)
core  

Data‐Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño, Shekeeb S. Mohammad, Rajeshwar Reddy Angiti, Velda Han, Michel Tchan, Russell C. Dale, Victor S.C. Fung   +6 more
wiley   +1 more source